dehydration; diarrhea; abdominal pain; vomiting aggravated/ incoercible vomiting; this is a spontaneous report received from a contactable reporter(s) (consumer or other non hcp) from the regulatory authority-web. regulatory number: it-minisal02-842874. a 44 year-old male patient received bnt162b2 (comirnaty, solution for injection), intramuscular, administered in deltoid left, administration date 14oct2021 10:53 (lot number: fg3739) as dose number unknown, single for covid-19 immunisation. relevant medical history included: "allergy to various food" (unspecified if ongoing); "arterial hypertension" (unspecified if ongoing), notes: in pharmacological treatment.; "dyslipidemia" (unspecified if ongoing). the patient's concomitant medications were not reported. the following information was reported: vomiting (hospitalization) with onset 14oct2021, outcome "recovered with sequelae", described as "vomiting aggravated/ incoercible vomiting"; dehydration (hospitalization) with onset 18oct2021, outcome "recovered with sequelae", described as "dehydration"; diarrhoea (hospitalization) with onset 14oct2021, outcome "recovered with sequelae", described as "diarrhea"; abdominal pain (hospitalization) with onset 14oct2021, outcome "recovered with sequelae", described as "abdominal pain". therapeutic measures were taken as a result of vomiting, dehydration, diarrhoea, abdominal pain. clinical information: actions taken (liquid-based treatments, re-integration of serum electrolytes, antiemetics and anti-acids-). impact on the quality of life (8/10). no follow-up attempts are possible. no further information is expected